Pill burden decreases and antiretroviral regimens simplify for many of the participants who start lenacapavir.

Jefferies London Healthcare Conference 2025 November 17, 2025 10:00 AM ESTCompany ParticipantsLawrence Blatt - ...

Explore the advantages of virtual screening in drug discovery, offering rapid evaluation and cost savings over traditional ...

Atea Pharmaceuticals, Inc. ( AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements November 13, 2025 10:00 AM EST Jordan Feld Anthony Martinez Nancy Reau Eric ...

Water Activation: One of the aspartic acid residues acts as a general base, activating a water molecule by abstracting a proton, while the other aspartic acid residue acts as a general acid, ...

However, in the mid-1980s, as the AIDS epidemic raged and scientists desperately searched for a way to combat the newly identified human immunodeficiency virus (HIV), researchers at the National ...

Researchers from the Institute of Human Virology (IHV) at the University of Maryland School of Medicine have discovered how a ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Researchers from the Institute of Human Virology (IHV) at the University of Maryland School of Medicine have discovered how a ...

ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to HIV-negative patients. Studies included in the review were mostly ...

Patients with and without HIV had similar 1- and 3-year survival outcomes following kidney transplantation, however, 5-year survival outcomes differed significantly.

Gilead Sciences has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. After comparing two phase 1 integrase strand transfer inhibitors, the Bay Area pharma ...